Bristol-Myers Squibb Quick Analysis

Bristol-Myers Squibb Quick Analysis

#Bristol-Myers Squibb could be on track to break out. The drugmaker said Monday that its current pipeline of drugs could generate $25 billion in annual revenue, enough to replace lost revenue from expired patents by 2030. Bristol-Myers Squibb closed up 0.460 at 65.430. Volume was 18% above average (neutral) and Bollinger Bands were 4% narrower than […]

Bristol-Myers Squibb (NYSE:BMY) Heffx Trading Outlook

Bristol-Myers Squibb (NYSE:BMY) Heffx Trading Outlook

Bristol-Myers Squibb (NYSE:BMY) Heffx Trading Outlook Overall, the bias in prices is: Downwards. Short term: Prices are moving. Intermediate term: Prices are trending. Note: this chart shows extraordinary price action to the downside. The projected upper bound is: 55.24. The projected lower bound is: 43.38. The projected closing price is: 49.31. Candlesticks A big black […]